Simon is Senior Director, Global Market and Pricing at Ipsen. He covers market access planning for pipeline and in-licensed products across Ipsen’s franchises of oncology, endocrinology and neurosciences. He also leads global market access for Ipsen’s Dysport ® brand.
Previously he has held various senior roles in international pharma consulting including IMS Consulting Group (now QuintilesIMS) and Pope Woodhead Associates where he led global assignments in pricing, managed entry scheme design, HTA policy, launch planning and value dossiers for orphan and oncology medicines. Previously, he led the medical innovation group at Sagentia Plc, specialising in commercialisation of implantables, drug delivery and diagnostics. In earlier roles Simon was policy adviser in biotechnology at the Confederation of British Industry and a Postdoctoral Fellow in Economics at London Business School. He holds a PhD in cell biology (UCL) and a Diploma in Public Affairs (CIPR).